Log In
BCIQ
Print this Print this
 

Ingrezza, valbenazine (MT-5199, NBI-98854)

Also known as: formerly VMAT2

  Manage Alerts
Collapse Summary General Information
Company Neurocrine Biosciences Inc.
DescriptionSelective vesicular monoamine transporter 2 (VMAT2; SLC18A2) inhibitor
Molecular Target Vesicular monoamine transporter 2 (VMAT2) (SLC18A2)
Mechanism of ActionVesicular monoamine transporter 2 inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$115.0M

$30.0M

$85.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/31/2015

$115.0M

$30.0M

$85.0M

Get a free BioCentury trial today